PEP-Therapy
Évry
About PEP-Therapy
PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $9.2M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Jul 2021)
- Website: pep-therapy.com
- Phone: +33 1 53 10 05 48
Industries & Categories
Biotechnology, Medical, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pep-therapy-107961 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.